H2N2V1, Main, Exploration, bibRecord, 002737

Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza

Identifieur interne : 002737 ( Main/Exploration ); précédent : 002736; suivant : 002738

Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza

Auteurs : John M. Quarles [États-Unis] ; Robert B. Couch [États-Unis] ; Thomas R. Cate [États-Unis] ; Claude B. Goswick [États-Unis]

Source :

Antiviral Research [ 0166-3542 ] ; 1981.

RBID : ISTEX:DE5B997D573CCF4E84D3F040D3FE3F6424B4C192

English descriptors

Teeft :
- Agents chemother, Amantadine, Amantadine group, Drug category, Fewer seroconversions, Greater effectiveness, Greater rise, Health center, High frequency, Illness occurrence, Influenza, Influenza virus, Less infection, Microtiter plates, Milder illness, National institute, Neutralizing antibody, Personal communication, Placebo, Placebo recipients, Present study, Protective effect, Rimantadine, Rimantadine hydrochloride, Seroconversion, Seroconversion frequencies, Seroconversion frequency, Seroconversions, Side effects, Study period, Weekly reports, Young adults.

Abstract

Abstract: The efficacies of 200 mg daily doses of amantadine and of rimantadine for prevention of infection and illness due to influenza A/USSR/77 (H1N1) virus were compared in a double-blind, placebo-controlled study on a college campus. Frequencies of symptoms that might have been side effects of the drugs were not significantly different from those in placebo recipients. Analyses indicated that the trial was initiated late in the epidemic and that an age-related protective effect against A/USSR virus existed; seroconversion frequencies were 52 139 (37%) among 18–19-year-olds, 33 130 (25%) among 20–21-year-olds, and 5 39 (12.8%) among 22–24-year-olds. Among initially antibody-negative (<1 : 4 in complement fixing and neutralizing tests and <1 : 8 in hemagglutination inhibition tests) 18–19-year-old students, amantadine was associated with significantly fewer seroconversions (P = 0.01) and both less infection and milder illness than occurred in placebo recipients (P<0.05). Although rimantadine was not accompanied by reduction in frequency of seroconversions in the same age group, illness frequency and severity among seroconverters were significantly reduced when compared to placebo recipients (P<0.01). Amantadine and rimantadine appear suitable for use in young adults. Although other studies have suggested greater effectiveness of rimantadine than of amantadine against influenza, no evidence for this was seen in the present study which used both drugs at the same dose.

Url:

https://api.istex.fr/ark:/67375/6H6-8D0N0H2H-F/fulltext.pdf

DOI: 10.1016/0166-3542(81)90003-6

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Istex, to step Corpus: 000397
to stream Istex, to step Curation: 000397
to stream Istex, to step Checkpoint: 001369
to stream Main, to step Merge: 002882
to stream Main, to step Curation: 002737

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title>Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza</title>
<author><name sortKey="Quarles, John M" sort="Quarles, John M" uniqKey="Quarles J" first="John M." last="Quarles">John M. Quarles</name>
</author>
<author><name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B." last="Couch">Robert B. Couch</name>
</author>
<author><name sortKey="Cate, Thomas R" sort="Cate, Thomas R" uniqKey="Cate T" first="Thomas R." last="Cate">Thomas R. Cate</name>
</author>
<author><name sortKey="Goswick, Claude B" sort="Goswick, Claude B" uniqKey="Goswick C" first="Claude B." last="Goswick">Claude B. Goswick</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:DE5B997D573CCF4E84D3F040D3FE3F6424B4C192</idno>
<date when="1981" year="1981">1981</date>
<idno type="doi">10.1016/0166-3542(81)90003-6</idno>
<idno type="url">https://api.istex.fr/ark:/67375/6H6-8D0N0H2H-F/fulltext.pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000397</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000397</idno>
<idno type="wicri:Area/Istex/Curation">000397</idno>
<idno type="wicri:Area/Istex/Checkpoint">001369</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">001369</idno>
<idno type="wicri:doubleKey">0166-3542:1981:Quarles J:comparison:of:amantadine</idno>
<idno type="wicri:Area/Main/Merge">002882</idno>
<idno type="wicri:Area/Main/Curation">002737</idno>
<idno type="wicri:Area/Main/Exploration">002737</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a">Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza</title>
<author><name sortKey="Quarles, John M" sort="Quarles, John M" uniqKey="Quarles J" first="John M." last="Quarles">John M. Quarles</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Medical Microbiology and Immunology, College of Medicine, Texas A & M University College Station</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B." last="Couch">Robert B. Couch</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Research Center, Department of Microbiology and Immunology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
<affiliation></affiliation>
</author>
<author><name sortKey="Cate, Thomas R" sort="Cate, Thomas R" uniqKey="Cate T" first="Thomas R." last="Cate">Thomas R. Cate</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Influenza Research Center, Department of Microbiology and Immunology, Baylor College of Medicine, Houston, TX 77030</wicri:regionArea>
<placeName><region type="state">Texas</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goswick, Claude B" sort="Goswick, Claude B" uniqKey="Goswick C" first="Claude B." last="Goswick">Claude B. Goswick</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Department of Medical Microbiology and Immunology, College of Medicine, Texas A & M University College Station</wicri:cityArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Antiviral Research</title>
<title level="j" type="abbrev">AVR</title>
<idno type="ISSN">0166-3542</idno>
<imprint><publisher>ELSEVIER</publisher>
<date type="published" when="1981">1981</date>
<biblScope unit="volume">1</biblScope>
<biblScope unit="issue">3</biblScope>
<biblScope unit="page" from="149">149</biblScope>
<biblScope unit="page" to="155">155</biblScope>
</imprint>
<idno type="ISSN">0166-3542</idno>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0166-3542</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Agents chemother</term>
<term>Amantadine</term>
<term>Amantadine group</term>
<term>Drug category</term>
<term>Fewer seroconversions</term>
<term>Greater effectiveness</term>
<term>Greater rise</term>
<term>Health center</term>
<term>High frequency</term>
<term>Illness occurrence</term>
<term>Influenza</term>
<term>Influenza virus</term>
<term>Less infection</term>
<term>Microtiter plates</term>
<term>Milder illness</term>
<term>National institute</term>
<term>Neutralizing antibody</term>
<term>Personal communication</term>
<term>Placebo</term>
<term>Placebo recipients</term>
<term>Present study</term>
<term>Protective effect</term>
<term>Rimantadine</term>
<term>Rimantadine hydrochloride</term>
<term>Seroconversion</term>
<term>Seroconversion frequencies</term>
<term>Seroconversion frequency</term>
<term>Seroconversions</term>
<term>Side effects</term>
<term>Study period</term>
<term>Weekly reports</term>
<term>Young adults</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Abstract: The efficacies of 200 mg daily doses of amantadine and of rimantadine for prevention of infection and illness due to influenza A/USSR/77 (H1N1) virus were compared in a double-blind, placebo-controlled study on a college campus. Frequencies of symptoms that might have been side effects of the drugs were not significantly different from those in placebo recipients. Analyses indicated that the trial was initiated late in the epidemic and that an age-related protective effect against A/USSR virus existed; seroconversion frequencies were 52 139 (37%) among 18–19-year-olds, 33 130 (25%) among 20–21-year-olds, and 5 39 (12.8%) among 22–24-year-olds. Among initially antibody-negative (<1 : 4 in complement fixing and neutralizing tests and <1 : 8 in hemagglutination inhibition tests) 18–19-year-old students, amantadine was associated with significantly fewer seroconversions (P = 0.01) and both less infection and milder illness than occurred in placebo recipients (P<0.05). Although rimantadine was not accompanied by reduction in frequency of seroconversions in the same age group, illness frequency and severity among seroconverters were significantly reduced when compared to placebo recipients (P<0.01). Amantadine and rimantadine appear suitable for use in young adults. Although other studies have suggested greater effectiveness of rimantadine than of amantadine against influenza, no evidence for this was seen in the present study which used both drugs at the same dose.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Texas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Quarles, John M" sort="Quarles, John M" uniqKey="Quarles J" first="John M." last="Quarles">John M. Quarles</name>
</region>
<name sortKey="Cate, Thomas R" sort="Cate, Thomas R" uniqKey="Cate T" first="Thomas R." last="Cate">Thomas R. Cate</name>
<name sortKey="Couch, Robert B" sort="Couch, Robert B" uniqKey="Couch R" first="Robert B." last="Couch">Robert B. Couch</name>
<name sortKey="Goswick, Claude B" sort="Goswick, Claude B" uniqKey="Goswick C" first="Claude B." last="Goswick">Claude B. Goswick</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002737 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002737 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    H2N2V1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:DE5B997D573CCF4E84D3F040D3FE3F6424B4C192
   |texte=   Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 14 19:59:40 2020. Site generation: Thu Mar 25 15:38:26 2021

	Serveur d'exploration H2N2
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration H2N2

Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza

Comparison of amantadine and rimantadine for prevention of type A (Russian) influenza

Source :

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri